Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John E Pimanda

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Blood|October 10, 2024
Seeing MDS through the lens of genomicsLachlin Vaughan, John E Pimanda
International Journal of Cancer|January 29, 2015
Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancersAnchit Khanna, John E Pimanda
Blood|February 2, 2023
DDX41: the poster child for familial MDS/AML grows upPeter Truong, John E Pimanda
The International Journal of Developmental Biology|August 17, 2010
Gene regulatory networks governing haematopoietic stem cell development and identityJohn E Pimanda, Berthold Göttgens
Blood|August 14, 2020
Titans awake: HMAs for virus-driven ATLChristopher J Jolly, John E Pimanda
The International Journal of Biochemistry & Cell Biology|September 22, 2012
Cell signalling pathways that mediate haematopoietic stem cell specificationJonathon Marks-Bluth, John E Pimanda
Cancer Research|November 9, 2013
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy targetAnchit Khanna, John E Pimanda, Jukka Westermarck
Blood|May 14, 2026
PU.1 inflames lower-risk MDSJulie A I Thoms, John E Pimanda
Stem Cells (Dayton, Ohio)|May 18, 2012
Concise review: Blood relatives: formation and regulation of hematopoietic stem cells by the basic helix-loop-helix transcription factors stem cell leukemia and lymphoblastic leukemia-derived sequence 1David J Curtis, Jessica M Salmon, John E Pimanda
Blood|October 14, 2021
To switch or not to switch: PU.1 expression is the questionJulie A I Thoms, John E Pimanda, Olaf Heidenreich
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Blood|October 10, 2024
Seeing MDS through the lens of genomicsLachlin Vaughan, John E Pimanda
International Journal of Cancer|January 29, 2015
Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancersAnchit Khanna, John E Pimanda
Blood|February 2, 2023
DDX41: the poster child for familial MDS/AML grows upPeter Truong, John E Pimanda
The International Journal of Developmental Biology|August 17, 2010
Gene regulatory networks governing haematopoietic stem cell development and identityJohn E Pimanda, Berthold Göttgens
Blood|August 14, 2020
Titans awake: HMAs for virus-driven ATLChristopher J Jolly, John E Pimanda
The International Journal of Biochemistry & Cell Biology|September 22, 2012
Cell signalling pathways that mediate haematopoietic stem cell specificationJonathon Marks-Bluth, John E Pimanda
Cancer Research|November 9, 2013
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy targetAnchit Khanna, John E Pimanda, Jukka Westermarck
Blood|May 14, 2026
PU.1 inflames lower-risk MDSJulie A I Thoms, John E Pimanda
Stem Cells (Dayton, Ohio)|May 18, 2012
Concise review: Blood relatives: formation and regulation of hematopoietic stem cells by the basic helix-loop-helix transcription factors stem cell leukemia and lymphoblastic leukemia-derived sequence 1David J Curtis, Jessica M Salmon, John E Pimanda
Blood|October 14, 2021
To switch or not to switch: PU.1 expression is the questionJulie A I Thoms, John E Pimanda, Olaf Heidenreich
Pageof 10